Cornelia Landersdorfer, PhD
Drug Delivery, Disposition and Dynamics
Monash Institute of Pharmaceutical Sciences
NHMRC Career Development Fellow
Senior Research Fellow
The area of antimicrobial pharmacokinetics / pharmacodynamics is about saving patients' lives by developing optimised treatments: the right antibiotic at the right dose and the right time.
Dr Landersdorfer's research focuses on designing innovative optimised antibiotic combination dosing strategies to combat multidrug-resistant bacteria that can cause life-threatening infections. She also develops novel mechanism-based mathematical models for concentrations and effects of antibiotics and other drugs to optimise patient therapy in clinical practice. Results from her research have impacted on treatment of patients in hospitals internationally. She was awarded a prestigious NHMRC Career Development Fellowship and received the ASCEPT Denis Wade J&J New Investigator Award in 2013. Outside of work Cornelia likes to practice her foreign language skills and also to explore bike trails around Melbourne.
Selected recent publications
Koomanachai P, Landersdorfer CB, Chen G, Lee HJ, Jitmuang A, Wasuwattakul S, Sritippayawan S, Li J, Nation RL, Thamlikitkul V. Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in End-Stage Renal Disease Patients Receiving Continuous Ambulatory Peritoneal Dialysis. Antimicrob Agents Chemother. 2014;58:440-6.
Landersdorfer CB, Ly NS, Xu H, Tsuji BT, Bulitta JB. Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design. Antimicrob Agents Chemother. 2013; 57:2343-51.
Sandri AM, Landersdorfer CB, Jacob J, Boniatti M, Dalarosa M, Falci D, Behle T, Saitovitch D, Wang J, Forrest A, Nation RL, Zavascki A, Li J. Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. Clin Infect Dis. 2013;57:524-31.
Landersdorfer CB, Bulitta JB, Kirkpatrick CMJ, Kinzig M, Holzgrabe U, Drusano GL, Stephan U, Sörgel F. Population Pharmacokinetics of Piperacillin at Two Dose Levels: Influence of Nonlinear Pharmacokinetics on the Pharmacodynamic Profile. Antimicrob Agents Chemother. 2012;56:5715-23.
Landersdorfer CB, He Y-L, Jusko WJ. Mechanism-Based Population Modelling of the Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients with Type 2 Diabetes. Br J Clin Pharmacol. 2012;73:373-90.